Compare Nuvalent Inc (NUVL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Zoetis Inc — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Zoetis Inc trades at $76.07 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 3.3× Nuvalent Inc's market cap, and Zoetis Inc pays a 2.78% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| NUVL | ZTS | |
|---|---|---|
Market Cap | $9.81B | $31.95B |
Sector | Technology | Health |
52-Week High | $123.96 | $156.76 |
52-Week Low | $72.16 | $71.91 |
Enterprise Value | $8.52B | $39.24B |
Dividend Yield | — | 2.78% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
